2 C
New York
Wednesday, February 1, 2023

Is ADMA Biologics Inc. (NASDAQ: ADMA) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for ADMA Biologics Inc. (ADMA) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.02, or -0.52%, to $3.85. The ADMA Biologics Inc. has recorded 27,814 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

ADMA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $3.87 and fluctuated between $3.9800 as its day high and $3.7812 as its day low. The current market capitalization of ADMA Biologics Inc. is $838.32M. A total of 3.12 million shares were traded on the day, compared to an average of 3.22M shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, ADMA has seen 3 BUY and 0 SELL insider trades, representing the acquisition of 36,958 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 6 SELLs from insiders. Insiders purchased 607,388 shares during that period but sold 384,679.

In the most recent transaction, Grossman Adam S bought 14,982 shares of ADMA for 2.86 per share on Dec 09. After the transaction, the President and CEO now owns 1,143,426 company shares. In a previous transaction on Dec 09, Grossman Adam S bought 14,983 shares at 2.86 per share. ADMA shares that President and CEO owns now total 2,203,708.

Among the insiders who bought shares, LENZ BRIAN acquired of 6,993 shares on Dec 09 at a per-share price of $2.86. This resulted in the EVP, CFO holding 1,034,825 shares of ADMA after the transaction.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ADMA in the last 3 months, the mean price target is $5.13 with high estimates of $6.00 and low estimates of $4.50. In terms of 52-week highs and lows, ADMA has a high of $3.92 and a low of $1.26.

As of this writing, ADMA has an earnings estimate of -$0.08 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.06 per share and a lower estimate of -$0.09. The company reported an EPS of -$0.13 in the last quarter, which was -62.50% lower than expectations of -$0.08.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ADMA is Buy with a score of 5.00. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles